Vortosiran in Atrial Fibrillation
brief summary
This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF. The trial consists of three groups including 50 participants each. The participants will be randomized to either the low dose group or the high dose group receiving vortosiran or to the group receiving apixaban. The treatment will be open-label for vortosiran vs apixaban. The vortosiran dose will be blinded to patients and investigators. Both the low- and the high-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, at the end of the vortosiran treatment period, the participants will start an open-label part of the trial and will be switched to standard-of-care apixaban treatment until Week 64 (End of Trial; EOT). Participants in the open-label apixaban arm will receive apixaban as standard of care during the entire trial.
detailed description
Atrial fibrillation (AF) is among the most prevalent cardiovascular conditions, affecting approximately 2 4% of the adult population worldwide. AF represents the most common sustained supraventricular arrhythmia and is associated with substantial morbidity, mortality, and health-care burden. Patients with AF are at an elevated risk of thromboembolic complications, particularly ischemic stroke and systemic embolism, while also facing an increased risk of bleeding associated with long-term antithrombotic therapy administered to prevent these complications. The principal aim of management in AF is to prevent stroke while minimizing haemorrhagic risk through careful risk stratification for both thromboembolic risk and bleeding risk, and informed and individualised treatment selections.
According to current guideline recommendations, oral anticoagulation is recommended for stroke prevention and may be guided by CHA2DS2 -VASc clinical risk assessment tool. Nonvitamin K antagonist oral anticoagulants (NOACs, also referred to as direct oral anticoagulants, or DOACs) are preferred over vitamin K antagonists (VKAs) in most cases due to their superior safety profile and lower incidence of intracranial bleeding. Bleeding risk can be assessed using validated tools such as HAS-BLED, and modifiable risk factors should be addressed to reduce overall treatment-related complications.
Despite a superior efficacy-safety profile of NOACs relative to VKAs, patients treated with NOACs remain at residual risk for stroke, systemic embolism, and cardiovascular mortality. Furthermore, although NOACs are associated with reduced rates of intracranial haemorrhage compared with VKAs, they still confer a considerable risk of major bleeding and clinically relevant non-major bleeding events. Consequently, the clinical need for strategies that further optimize the balance between thromboembolic prevention and bleeding risk in patients with AF remains.
Recent advances have positioned coagulation factor XI (FXI) inhibition as a promising strategy in anti-thrombotic drug development. FXI is a crucial element of the intrinsic coagulation pathway, and genetic FXI deficiency (haemophilia C) is typically associated with only mild bleeding even in complete deficiency, suggesting the potential for improved safety compared to conventional anti-thrombotic drugs by disengaging physiologic haemostasis from pathologic, intraluminal thrombosis. FXI inhibition reliably prolongs activated partial thromboplastin time (APTT) in vitro, and epidemiological studies demonstrate that inherited FXI deficiency confers protection against venous thromboembolism (VTE) and ischemic stroke. Conversely, elevated circulating activated FXI (FXIa) is linked to higher risks of ischemic stroke, VTE, and acute coronary syndrome (ACS). Contemporary research utilizing coagulometric assays has confirmed FXIa and tissue factor activation in patients with stable coronary artery disease, ACS of less than 12 hours' duration, and heart failure, reinforcing FXI's role as a pathogenic factor in these conditions.
official title
A Randomised Active-controlled Trial to Assess the Safety and Pharmacodynamics of Two Blinded Doses of Vortosiran and Open-label Apixaban in Patients With Non-valvular Atrial Fibrillation (AF)